Latest News - Allergan

Thursday, February 23, 2017 | Health Care, Allergan

Allergan CEO Pushes for Trump to Lead Drug Price Discussions

When asked about President Trump’s calls to deal with high US drug costs, Allergan Chief Executive Officer Brent Saunders told Bloomberg News that President Trump should lead negotiations with d…

Read the full story

Tuesday, February 14, 2017 | Glaucoma, Allergan

Allergan Announces First Commercial Use of XEN Glaucoma Treatment System in the US

Allergan announced that its XEN Glaucoma Treatment System is now being used by US surgeons to treat refractory glaucoma. The XEN Glaucoma Treatment System, consisting of the XEN45 Gel Stent and the XE…

Read the full story

Monday, February 13, 2017 | Acquisitions/Mergers, Allergan

Allergan to Acquire Zeltiq, Maker of CoolSculpting System, for $2.47 Billion

Allergan has agreed to acquire Zeltiq Aesthetics for $56.50 per share, or $2.475 billion, subject to customary adjustments, the companies announced in a news release. T Allergan said the acquisitio…

Read the full story

Tuesday, February 07, 2017 | Partnerships, Allergan

Allergan Launches 'See America,' an Initiative Furthering the Fight Against Preventable Blindness

Allergan announced a commitment to fight preventable blindness in the United States with a new initiative -- See America. Through See America, Allergan sets out to make vision health a priority for al…

Read the full story

Thursday, December 22, 2016 | Management/Leadership, Allergan

Allergan’s CEO Has Struck an Insane Number of Biotech Deals

Allergan chief Brent Saunders has had a pretty remarkable career trajectory. He headed up Bausch & Lomb until the eye care specialist was snatched up by the (now-infamous) Valeant Pharmaceuticals;…

Read the full story

Wednesday, December 21, 2016 | Acquisitions/Mergers, Allergan

Allergan to Acquire Acelity LifeCell Corporation for $2.9 Billion

Allergan and Acelity announced that they have entered into a definitive agreement under which Allergan has agreed to acquire the regenerative medicine company LifeCell for $2.9 billion in cash. The…

Read the full story

Friday, December 02, 2016 | Health Care, Allergan

Allergan CEO: 'I Worry Today that Pharma has a False Sense of Relief or Security' with Trump Presidency

Investors betting that Donald Trump is going to lay off the drug industry might be in for a surprise, according to the CEO of Botox maker Allergan. Drug stocks have were among the biggest gainers in t…

Read the full story

Tuesday, November 22, 2016 | FDA Approval/Clearance, Product Releases, Allergan

Allergan Receives FDA Clearance for the XEN Gel Stent, a New Surgical Treatment for Refractory Glaucoma

Allergan announced that the FDA has cleared the XEN Glaucoma Treatment System, which consists of the XEN45 Gel Stent and the XEN Injector. The XEN Glaucoma Treatment System reduces IOP in patients and…

Read the full story

Thursday, November 10, 2016 | Medical Studies, Allergan

New Report Explores Divide Between Managed Care and Eye Care Professionals

The Eye Care Trend Report, Volume II, supported by Allergan, is now available. The award-winning, 40-page report examines and compares the perspectives of managed care organizations (MCOs), ophthalmol…

Read the full story

Thursday, November 03, 2016 | Earnings & Financials, Allergan

Allergan Initiates Dividend and Expands Stock Buyback as It Eschews Megadeals

Allergan PLC on Wednesday lowered its outlook, saying sales of some drugs were weaker than expected. The company also said it would return more cash to shareholders because the drugmaker isn’t i…

Read the full story

Friday, October 28, 2016 | Product Releases, Allergan

Allergan Introduces Preservative-Free Restasis Multidose

Allergan announced that it has received approval from the FDA for Restasis Multidose (cyclosporine ophthalmic emulsion) 0.05%, a preservative-free, multidose bottle offering the same preservative…

Read the full story

Monday, October 10, 2016 | Conferences, Allergan

Allergan to Showcase Expanding Eye Care Portfolio with New Data Presentations at the American Academy of Ophthalmology Meeting

Allergan announced that its data will be presented during the 2016 American Academy of Ophthalmology (AAO) Annual Meeting in Chicago, October 14-18. The scheduled times (noted in local Central Time) o…

Read the full story

Wednesday, September 14, 2016 | Acquisitions/Mergers, Allergan

Allergan Boosts its Dermatology Portfolio with Acquisition of Vitae Pharmaceuticals

Allergan and Vitae Pharmaceuticals announced that they have entered into a definitive agreement under which Allergan will acquire Vitae for $21 per share, in cash, for a total transaction value of app…

Read the full story

Tuesday, September 06, 2016 | Acquisitions/Mergers, Allergan, RetroSense Therapeutics

Allergan Acquires Gene Therapy Company RetroSense Therapeutics

Allergan has acquired RetroSense Therapeutics, a private, clinical-stage biotechnology company focused on gene therapy approaches to restore vision in patients suffering from blindness, in an all-cash…

Read the full story

Thursday, August 11, 2016 | Acquisitions/Mergers, Glaucoma, Allergan, ForSight Vision

Allergan Acquires ForSight VISION5

Allergan and ForSight VISION5 announced have entered into an agreement under which Allergan will acquire ForSight VISION5 for a $95 million upfront payment and a launch milestone payment related to Fo…

Read the full story
Load More